RNA 治療市場 - 按產品、類型、適應症、最終用途、全球預測，2024 年 - 2032 年

在癌症、遺傳性疾病和傳染病等慢性疾病盛行率不斷上升的推動下，RNA 療法市場規模預計在 2024 年至 2032 年間以 5.7% 的複合年成長率創紀錄。根據美國國立衛生研究院(NIH) 的數據，2023 年，美國RNA 療法出現了近1,958,310 例新癌症病例和609,820 例癌症死亡，這為透過針對特定基因和途徑提供更有效和個性化的治療方法來解決這些疾病提供了潛力。 RNA 遞送技術（例如脂質奈米粒子和病毒載體）的進步正在增強基於 RNA 的藥物的功效和安全性。

此外，圍繞 RNA 療法的監管環境正在不斷發展，監管機構越來越認知到基於 RNA 的藥物在簡化核准流程方面的潛力。在基因組定序和分子診斷進步的推動下，個人化醫療方法的日益普及也為 RNA 療法精確地針對特定患者群體創造了機會。隨著全球醫療保健系統努力改善患者治療效果並降低醫療成本，對創新和標靶治療的需求預計將推動產業成長。

RNA 治療市場根據產品、類型、適應症、最終用途和地區進行分類。

根據跡象，到 2032 年，自體免疫疾病領域的產業規模預計將達到 6% 的複合年成長率，其特徵是針對人體自身組織的免疫反應失調。 RNA療法透過針對參與免疫失調的特定分子途徑，為治療自體免疫疾病提供了一條有前景的途徑。此外，基於RNA的技術的進步，例如反義寡核苷酸和小干擾RNA，能夠精確調節與自體免疫疾病相關的基因表達，從而提供潛在的治療益處。

就最終用途而言，學術和研究機構領域的RNA 治療市場預計在2024 年和2032 年期間複合年成長率為5.4%。點並開發創新藥物基於RNA的療法。此外，學術和研究機構充當人才和創新的孵化器，培養下一代科學家和企業家，進一步推動該領域的成長。

亞太地區RNA治療產業在2024年至2032年間將以6.1%的複合年成長率大幅成長，原因是人口眾多且多樣化，加上傳染病和慢性病的高盛行率。以學術研究機構、生物製藥公司和政府措施網路為特徵的強大生物技術生態系統的存在正在促進 RNA 治療領域的多項研發活動。此外，有利的監管政策以及對醫療基礎設施和生物技術的投資增加將刺激區域產業的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 傳染病發生率上升
    • RNA 遞送技術的進步
    • 加強市場參與者之間的夥伴關係和合作
  • 產業陷阱與挑戰
    • RNA治療產品召回
    • 開發和製造成本高
• 成長潛力分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

• 主要趨勢
• 疫苗
• 藥品

第 6 章：市場估計與預測：按類型，2018 - 2032

• 主要趨勢
• mRNA療法
• 反義寡核苷酸（ASO）療法
• siRNA（小干擾RNA）療法
• RNA 干擾 (RNAi) 療法
• 其他類型

第 7 章：市場估計與預測：按指標分類，2018 年 - 2032 年

• 主要趨勢
• 傳染性疾病
• 遺傳/遺傳疾病
• 自體免疫疾病
• 其他適應症

第 8 章：市場估計與預測：依最終用途，2018 - 2032 年

• 醫院
  • 私人的
  • 民眾
• 學術及研究機構
• 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 10 章：公司簡介

• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• BioNTech SE
• Ionis Pharmaceuticals
• Moderna Inc.
• Novartis AG
• Orna Therapeutics, Inc.
• Pfizer Inc.
• Sanofi
• Sarepta Therapeutics, Inc.

RNA therapeutics market size is set to record 5.7% CAGR of between 2024 and 2032, driven by the increasing prevalence of chronic disorders, such as cancer, genetic disorders, and infectious diseases. As per National Institutes of Health (NIH), in 2023, nearly 1,958,310 new cancer cases and 609,820 cancer deaths occurred in the U.S. RNA therapeutics offer the potential to address these diseases by targeting specific genes and pathways for providing more effective and personalized treatment approaches. Advancements in RNA delivery technologies, such as lipid nanoparticles and viral vectors, are enhancing the efficacy and safety profile of RNA-based drugs.

Moreover, the regulatory landscape surrounding RNA therapeutics is evolving, with regulatory agencies increasingly recognizing the potential of RNA-based drugs for streamlining the approval process. The growing adoption of personalized medicine approaches, driven by advancements in genomic sequencing and molecular diagnostics is also creating opportunities for RNA therapeutics to target specific patient populations with precision. As healthcare systems worldwide strive to improve patient outcomes and reduce healthcare costs, the demand for innovative and targeted therapies is expected to bolster the industry growth.

The RNA therapeutics market is classified on the basis of product, type, indication, end-use and region.

Based on indication, the industry size from the autoimmune disorder segment is slated to record a 6% CAGR through 2032, characterized by dysregulated immune responses targeting the body's own tissues. RNA therapeutics offer a promising avenue for treating autoimmune diseases by targeting specific molecular pathways involved in immune dysregulation. Additionally, advancements in RNA-based technologies, such as antisense oligonucleotides and small interfering RNAs, enable precise modulation of gene expression associated with autoimmune disorders, thereby offering potential therapeutic benefits.

In terms of end-use, the RNA therapeutics market from the academic & research institutes segment is anticipated to observe a 5.4% CAGR during 2024 and 2032. This is driven by advancements in the understanding of RNA biology for uncovering novel therapeutic targets and developing innovative RNA-based therapies. Moreover, academic and research institutes serve as incubators for talent and innovation for nurturing the next generation of scientists and entrepreneurs, further propelling the segment growth.

Asia Pacific RNA therapeutics industry will grow substantially at 6.1% CAGR between 2024 and 2032, attributed to the large and diverse population coupled with the high prevalence of infectious and chronic diseases. The presence of a robust biotechnology ecosystem, characterized by a network of academic research institutions, biopharmaceutical companies, and government initiatives is fostering multiple R&D activities in RNA therapeutics. Furthermore, favorable regulatory policies and increasing investments in healthcare infrastructure and biotechnology will stimulate the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculation
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of infectious diseases
    • 3.2.1.2 Advancements in RNA delivery technologies
    • 3.2.1.3 Increasing partnerships and collaborations among market players
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Recall of RNA therapeutic products
    • 3.2.2.2 High cost of development and manufacturing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vaccines
• 5.3 Drugs

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 mRNA therapeutics
• 6.3 Antisense oligonucleotide (ASO) therapeutics
• 6.4 siRNA (small interfering RNA) therapeutics
• 6.5 RNA interference (RNAi) therapeutics
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Infectious diseases
• 7.3 Hereditary/genetic diseases
• 7.4 Autoimmune disorders
• 7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Hospitals
  • 8.1.1 Private
  • 8.1.2 Public
• 8.2 Academic & research institutes
• 8.3 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alnylam Pharmaceuticals, Inc.
• 10.2 Arrowhead Pharmaceuticals, Inc.
• 10.3 BioNTech SE
• 10.4 Ionis Pharmaceuticals
• 10.5 Moderna Inc.
• 10.6 Novartis AG
• 10.7 Orna Therapeutics, Inc.
• 10.8 Pfizer Inc.
• 10.9 Sanofi
• 10.10 Sarepta Therapeutics, Inc.